recet and semaglutide procedure plus may eliminate insulin dependency in T2D ReCET procedure plus semaglutide may

So what do we actually do about GLP-1 face

Design Systematic review and network meta-analysis

Prusogliptin, developed by CSPC Ouyi Pharmaceutical, is a novel oral dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved by NMPA on January 8, 2025.

95% CI 1.66, 1.95

Advanced Prebiotic Technology PreforPro bacteriophage technology provides selective microbiome support, working alongside traditional prebiotics to promote beneficial bacteria without adding fermentable fibers that can trigger bloating

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice